Could Pfizer's and Lilly's Long-Awaited Osteoarthritis Drug Flop?
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) have worked together for years on the development of an osteoarthritis pain drug, tanezumab. In this Motley Fool Live video recorded on March 24, 2021, Motley Fool contributors Keith Speights and Brian Orelli talked about the hurdles the two companies must jump to win U.S. approval for the drug. (Note: A U.S. Food and Drug Administration [FDA] Advisory Committee voted 19-1 against tanezumab on March 25. The FDA has not yet made a final decision on approval of the drug.)
Source Fool.com
